|
PolyPeptide Group AG (0AAJ.L) DCF Valuation |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
PolyPeptide Group AG (0AAJ.L) Bundle
Discover the true worth of PolyPeptide Group AG (0AAJL) with our advanced DCF Calculator! Adjust crucial assumptions, explore various scenarios, and evaluate how shifts affect PolyPeptide Group AG (0AAJL) valuation – all within one convenient Excel template.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 211.3 | 265.8 | 264.7 | 301.8 | 319.0 | 355.0 | 395.1 | 439.6 | 489.2 | 544.4 |
| Revenue Growth, % | 0 | 25.78 | -0.40691 | 14.02 | 5.72 | 11.28 | 11.28 | 11.28 | 11.28 | 11.28 |
| EBITDA | 55.1 | 78.5 | 33.6 | -20.9 | 26.8 | 49.6 | 55.2 | 61.4 | 68.3 | 76.0 |
| EBITDA, % | 26.1 | 29.54 | 12.71 | -6.91 | 8.39 | 13.97 | 13.97 | 13.97 | 13.97 | 13.97 |
| Depreciation | 16.5 | 19.5 | 24.6 | 28.7 | 30.8 | 31.0 | 34.4 | 38.3 | 42.7 | 47.5 |
| Depreciation, % | 7.82 | 7.33 | 9.28 | 9.51 | 9.66 | 8.72 | 8.72 | 8.72 | 8.72 | 8.72 |
| EBIT | 38.6 | 59.0 | 9.1 | -49.6 | -4.0 | 18.6 | 20.7 | 23.1 | 25.7 | 28.6 |
| EBIT, % | 18.28 | 22.21 | 3.44 | -16.42 | -1.27 | 5.25 | 5.25 | 5.25 | 5.25 | 5.25 |
| Total Cash | 16.2 | 128.4 | 35.4 | 90.2 | 64.3 | 84.8 | 94.3 | 105.0 | 116.8 | 130.0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 52.3 | 63.9 | 46.3 | 74.2 | 81.3 | 82.6 | 91.9 | 102.3 | 113.8 | 126.7 |
| Account Receivables, % | 24.76 | 24.03 | 17.49 | 24.59 | 25.47 | 23.27 | 23.27 | 23.27 | 23.27 | 23.27 |
| Inventories | 88.8 | 106.4 | 136.7 | 121.1 | 137.9 | 154.1 | 171.5 | 190.8 | 212.4 | 236.3 |
| Inventories, % | 42.03 | 40.05 | 51.63 | 40.11 | 43.21 | 43.41 | 43.41 | 43.41 | 43.41 | 43.41 |
| Accounts Payable | 26.7 | 26.8 | 43.3 | 57.4 | 69.0 | 56.6 | 63.0 | 70.1 | 78.0 | 86.8 |
| Accounts Payable, % | 12.64 | 10.1 | 16.35 | 19.01 | 21.63 | 15.95 | 15.95 | 15.95 | 15.95 | 15.95 |
| Capital Expenditure | -38.3 | -69.7 | -70.7 | -53.4 | -81.9 | -81.3 | -90.4 | -100.6 | -112.0 | -124.6 |
| Capital Expenditure, % | -18.11 | -26.22 | -26.73 | -17.71 | -25.68 | -22.89 | -22.89 | -22.89 | -22.89 | -22.89 |
| Tax Rate, % | -7.82 | -7.82 | -7.82 | -7.82 | -7.82 | -7.82 | -7.82 | -7.82 | -7.82 | -7.82 |
| EBITAT | 32.1 | 46.6 | 9.3 | -43.8 | -4.4 | 16.8 | 18.7 | 20.8 | 23.1 | 25.7 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -104.0 | -32.6 | -33.1 | -66.7 | -67.7 | -63.5 | -57.6 | -64.1 | -71.3 | -79.4 |
| WACC, % | 9.32 | 9.26 | 9.57 | 9.4 | 9.57 | 9.42 | 9.42 | 9.42 | 9.42 | 9.42 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -255.4 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -81 | |||||||||
| Terminal Value | -1,091 | |||||||||
| Present Terminal Value | -695 | |||||||||
| Enterprise Value | -951 | |||||||||
| Net Debt | 24 | |||||||||
| Equity Value | -975 | |||||||||
| Diluted Shares Outstanding, MM | 33 | |||||||||
| Equity Value Per Share | -29.55 |
What You Will Receive
- Accurate PolyPeptide Financial Data: Pre-filled with historical and projected figures for in-depth analysis of PolyPeptide Group AG (0AAJL).
- Customizable Template: Easily adjust key variables such as revenue growth, WACC, and EBITDA percentage.
- Instant Calculations: Witness real-time updates of PolyPeptide’s intrinsic value as you modify inputs.
- Professional Valuation Tool: Tailored for investors, analysts, and consultants aiming for precise DCF outcomes.
- User-Friendly Interface: Intuitive layout and straightforward instructions suitable for all skill levels.
Key Features
- Comprehensive DCF Calculator: Features in-depth unlevered and levered DCF valuation models tailored for PolyPeptide Group AG (0AAJL).
- WACC Calculator: Ready-to-use Weighted Average Cost of Capital sheet with adjustable parameters.
- Customizable Forecast Assumptions: Alter growth rates, capital expenditures, and discount rates to fit your analysis.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios specifically for PolyPeptide Group AG (0AAJL).
- Visual Dashboard and Charts: Graphical representations for quick access to key valuation metrics.
How It Works
- Step 1: Download the Excel spreadsheet.
- Step 2: Explore the pre-filled financial data and projections for PolyPeptide Group AG (0AAJL).
- Step 3: Adjust key variables such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model refresh in real-time as you modify your assumptions.
- Step 5: Evaluate the outputs and leverage the findings for informed investment decisions.
Why Choose the PolyPeptide Group AG Calculator?
- Save Time: Skip the hassle of building a DCF model from the ground up – it's ready for immediate use.
- Enhance Accuracy: Access dependable financial data and formulas to minimize valuation errors.
- Completely Customizable: Adapt the model to align with your specific assumptions and forecasts.
- User-Friendly: Intuitive charts and outputs simplify the analysis of results.
- Endorsed by Professionals: Crafted for experts who prioritize both precision and ease of use.
Who Can Benefit from This Product?
- Finance Students: Master valuation techniques and apply them with real-world data.
- Academics: Integrate professional valuation models into your coursework or research projects.
- Investors: Validate your assumptions and evaluate valuation results for PolyPeptide Group AG (0AAJL).
- Analysts: Enhance your efficiency with a ready-made, customizable DCF model.
- Small Business Owners: Understand how major public companies like PolyPeptide Group AG (0AAJL) are analyzed in the market.
Contents of the Template
- Preloaded 0AAJL Data: Historical and projected financial information, encompassing revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Advanced worksheets for calculating intrinsic value and the Weighted Average Cost of Capital.
- Editable Inputs: Cells highlighted in yellow for modifying revenue growth, tax rates, and discount rates.
- Financial Statements: In-depth annual and quarterly financial data for thorough analysis.
- Key Ratios: Metrics for profitability, leverage, and efficiency to assess performance.
- Dashboard and Charts: Visual representations of valuation results and underlying assumptions.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.